Soft Tissue Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major soft tissue sarcoma markets reached a value of US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.7 Billion by 2034, exhibiting a growth rate (CAGR) of 5.31% during 2024-2034.
The soft tissue sarcoma market has been comprehensively analyzed in IMARC's new report titled "Soft Tissue Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Soft tissue sarcoma refers to an uncommon form of cancer that develops in the tissues that surround, connect, and support other body structures. This includes the muscle, fat, blood vessels, nerves, ligaments, and the lining of the joints. The tumors can occur anywhere in the body, although they most commonly form in the limbs, legs, chest, or abdomen. An initial symptom associated with the ailment is a painless lump or swelling in soft tissue. As the tumor increases in size, individuals suffering from this condition may experience other indications, such as pain or soreness. In rare cases, soft tissue sarcomas may cause numbness or tingling if they press on nerves. The diagnosis of the disease is based on a review of the patient's symptoms, medical history, and physical exam. The healthcare provider may also perform various imaging studies, including ultrasound, computed tomography scan, MRI, etc. A needle aspiration biopsy is further required to confirm a diagnosis among patients. In some cases, additional procedures, such as blood tests and a PET scan, may be ordered to check for the spread of cancer to other parts of the body.
The rising prevalence of inherited syndromes, resulting in DNA variations that influence the genes controlling cell proliferation, is primarily driving the soft tissue sarcoma market. In addition to this, the increasing cases of chemical exposure, such as from herbicides, arsenic, dioxin, etc., which can lead to tissue destruction, are also propelling the market growth. Furthermore, the escalating utilization of antineoplastic vascular endothelial growth factor (VEGF) for treating the ailment is creating a positive outlook for the market. This therapy can stop the growth and development of tumors by prohibiting angiogenesis through the inhibition of the VEGF pathway. Additionally, the inflating usage of laparoscopic or robotic surgery owing to its numerous benefits, including a shorter hospital stay, minimal complications, less scarring, etc., is also bolstering the market growth. Moreover, several stakeholders are making extensive investments in R&D activities to introduce effective targeted therapy as a novel treatment alternative for conventional procedures. This, in turn, is acting as another significant growth-inducing factor. In line with this, the emerging popularity of radiation therapies, such as brachytherapy, since they have a lower risk of complications than surgery and can treat tumors in hard-to-reach areas, is expected to drive the soft tissue sarcoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the soft tissue sarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for soft tissue sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the soft tissue sarcoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the soft tissue sarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the soft tissue sarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current soft tissue sarcoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the soft tissue sarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the soft tissue sarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the soft tissue sarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of soft tissue sarcoma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of soft tissue sarcoma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of soft tissue sarcoma by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of soft tissue sarcoma by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with soft tissue sarcoma across the seven major markets?
What is the size of the soft tissue sarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of soft tissue sarcoma?
What will be the growth rate of patients across the seven major markets?
Soft Tissue Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for soft tissue sarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the soft tissue sarcoma market?
What are the key regulatory events related to the soft tissue sarcoma market?
What is the structure of clinical trial landscape by status related to the soft tissue sarcoma market?
What is the structure of clinical trial landscape by phase related to the soft tissue sarcoma market?
What is the structure of clinical trial landscape by route of administration related to the soft tissue sarcoma market?
The soft tissue sarcoma market has been comprehensively analyzed in IMARC's new report titled "Soft Tissue Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Soft tissue sarcoma refers to an uncommon form of cancer that develops in the tissues that surround, connect, and support other body structures. This includes the muscle, fat, blood vessels, nerves, ligaments, and the lining of the joints. The tumors can occur anywhere in the body, although they most commonly form in the limbs, legs, chest, or abdomen. An initial symptom associated with the ailment is a painless lump or swelling in soft tissue. As the tumor increases in size, individuals suffering from this condition may experience other indications, such as pain or soreness. In rare cases, soft tissue sarcomas may cause numbness or tingling if they press on nerves. The diagnosis of the disease is based on a review of the patient's symptoms, medical history, and physical exam. The healthcare provider may also perform various imaging studies, including ultrasound, computed tomography scan, MRI, etc. A needle aspiration biopsy is further required to confirm a diagnosis among patients. In some cases, additional procedures, such as blood tests and a PET scan, may be ordered to check for the spread of cancer to other parts of the body.
The rising prevalence of inherited syndromes, resulting in DNA variations that influence the genes controlling cell proliferation, is primarily driving the soft tissue sarcoma market. In addition to this, the increasing cases of chemical exposure, such as from herbicides, arsenic, dioxin, etc., which can lead to tissue destruction, are also propelling the market growth. Furthermore, the escalating utilization of antineoplastic vascular endothelial growth factor (VEGF) for treating the ailment is creating a positive outlook for the market. This therapy can stop the growth and development of tumors by prohibiting angiogenesis through the inhibition of the VEGF pathway. Additionally, the inflating usage of laparoscopic or robotic surgery owing to its numerous benefits, including a shorter hospital stay, minimal complications, less scarring, etc., is also bolstering the market growth. Moreover, several stakeholders are making extensive investments in R&D activities to introduce effective targeted therapy as a novel treatment alternative for conventional procedures. This, in turn, is acting as another significant growth-inducing factor. In line with this, the emerging popularity of radiation therapies, such as brachytherapy, since they have a lower risk of complications than surgery and can treat tumors in hard-to-reach areas, is expected to drive the soft tissue sarcoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the soft tissue sarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for soft tissue sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the soft tissue sarcoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the soft tissue sarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the soft tissue sarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current soft tissue sarcoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the soft tissue sarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the soft tissue sarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the soft tissue sarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of soft tissue sarcoma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of soft tissue sarcoma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of soft tissue sarcoma by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of soft tissue sarcoma by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with soft tissue sarcoma across the seven major markets?
What is the size of the soft tissue sarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of soft tissue sarcoma?
What will be the growth rate of patients across the seven major markets?
Soft Tissue Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for soft tissue sarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the soft tissue sarcoma market?
What are the key regulatory events related to the soft tissue sarcoma market?
What is the structure of clinical trial landscape by status related to the soft tissue sarcoma market?
What is the structure of clinical trial landscape by phase related to the soft tissue sarcoma market?
What is the structure of clinical trial landscape by route of administration related to the soft tissue sarcoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOFT TISSUE SARCOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SOFT TISSUE SARCOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SOFT TISSUE SARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 SOFT TISSUE SARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SOFT TISSUE SARCOMA - UNMET NEEDS
10 SOFT TISSUE SARCOMA - KEY ENDPOINTS OF TREATMENT
11 SOFT TISSUE SARCOMA - MARKETED PRODUCTS
11.1 List of Soft Tissue Sarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Yondelis (Trabectedin) - Johnson & Johnson
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Lartruvo (Olaratumab) - Eli Lilly and Company
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Votrient (Pazopanib) - GlaxoSmithKline/Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Ayvakit (Avapritinib) - Blueprint Medicines
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SOFT TISSUE SARCOMA - PIPELINE DRUGS
12.1 List of Soft Tissue Sarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Camsirubicin (GPX 150) - Monopar Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Aldoxorubicin - ImmunityBio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AL3818 - Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Onfekafusp alfa (L19TNF?) - Philogen
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 NBTXR3 - Nanobiotix
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SOFT TISSUE SARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SOFT TISSUE SARCOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SOFT TISSUE SARCOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Soft Tissue Sarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Soft Tissue Sarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Soft Tissue Sarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Soft Tissue Sarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Soft Tissue Sarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Soft Tissue Sarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Soft Tissue Sarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Soft Tissue Sarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Soft Tissue Sarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Soft Tissue Sarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Soft Tissue Sarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Soft Tissue Sarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Soft Tissue Sarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Soft Tissue Sarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Soft Tissue Sarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Soft Tissue Sarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
16 SOFT TISSUE SARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SOFT TISSUE SARCOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SOFT TISSUE SARCOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOFT TISSUE SARCOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SOFT TISSUE SARCOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SOFT TISSUE SARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 SOFT TISSUE SARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SOFT TISSUE SARCOMA - UNMET NEEDS
10 SOFT TISSUE SARCOMA - KEY ENDPOINTS OF TREATMENT
11 SOFT TISSUE SARCOMA - MARKETED PRODUCTS
11.1 List of Soft Tissue Sarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Yondelis (Trabectedin) - Johnson & Johnson
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Lartruvo (Olaratumab) - Eli Lilly and Company
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Votrient (Pazopanib) - GlaxoSmithKline/Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Ayvakit (Avapritinib) - Blueprint Medicines
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SOFT TISSUE SARCOMA - PIPELINE DRUGS
12.1 List of Soft Tissue Sarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Camsirubicin (GPX 150) - Monopar Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Aldoxorubicin - ImmunityBio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AL3818 - Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Onfekafusp alfa (L19TNF?) - Philogen
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 NBTXR3 - Nanobiotix
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SOFT TISSUE SARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SOFT TISSUE SARCOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SOFT TISSUE SARCOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Soft Tissue Sarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Soft Tissue Sarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Soft Tissue Sarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Soft Tissue Sarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Soft Tissue Sarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Soft Tissue Sarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Soft Tissue Sarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Soft Tissue Sarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Soft Tissue Sarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Soft Tissue Sarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Soft Tissue Sarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Soft Tissue Sarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Soft Tissue Sarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Soft Tissue Sarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Soft Tissue Sarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Soft Tissue Sarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Soft Tissue Sarcoma - Access and Reimbursement Overview
16 SOFT TISSUE SARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SOFT TISSUE SARCOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SOFT TISSUE SARCOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
